Evidence map›Paper›PMID 28497065›Full record

Trial reportBioMed research international2017

A Low Psoas Muscle Index before Treatment Can Predict a Poorer Prognosis in Advanced Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.

Ryo Kasahara, Takashi Kawahara, Shinji Ohtake, Yoko Saitoh, Sohgo Tsutsumi, Jun-Ichi Teranishi, Yasuhide Miyoshi, Noboru Nakaigawa, Masahiro Yao, Kazuki Kobayashi and 1 more

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Sarcopenia in Patients with Chronic Thromboembolic Pulmonary Hypertension.Journal of cardiovascular development and disease · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ryo KasaharaDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.ORCID 0000-0002-2564-2793
Takashi KawaharaDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.ORCID 0000-0002-7049-3379
Shinji OhtakeDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.
Yoko SaitohDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.
Sohgo TsutsumiDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.
Jun-Ichi TeranishiDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.
Yasuhide MiyoshiDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.
Noboru NakaigawaDepartment of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID 0000-0002-7228-3447
Masahiro YaoDepartment of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kazuki KobayashiDepartment of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
Hiroji UemuraDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama, Japan.ORCID 0000-0003-3775-2671
Yokohama City University Medical Center · JPYokohama City University · JPYokosuka Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Psoas MusclesUrinary Bladder NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDisease-Free SurvivalFemaleGemcitabineHumansMaleMiddle AgedOrganoplatinum CompoundsSurvival RateDeoxycytidineGemcitabinenedaplatinOrganoplatinum Compounds

Identifiers

PMID28497065
PMCPMC5406717
OpenAlexW2606088274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.